Journal of Medicinal Chemistry · 1996 · 61 citations · 47 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructural BiologyEnzyme InhibitionLead Compound DesignLigand BindingNatural Product Drug DiscoveryProtein StructureStructure-activity Relationship AnalysisChemical Library SynthesisCis-trans IsomerismCis-trans Peptide IsomerizationInhibition ConstantsNatural Product PharmacologyStructure-guided Lead Discovery
The structure-based design and subsequent chemical synthesis of novel, urea-containing FKBP12 inhibitors are described. These compounds are shown to disrupt the cis-trans peptidylprolyl isomerase activity of FKBP12 with inhibition constants (Ki,app) approaching 0.10 microM. Analyses of several X-ray crystal structures of FKBP12-urea complexes demonstrate that the urea-containing inhibitors associate with FKBP12 in a manner that is similar to, but significantly different from, that observed for the natural product FK506.
47
Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins
Günter Fischer, Brigitte Wittmann‐Liebold, Kurt Lang et al. · Nature · 1989 · 1.4K citations